Drugs / A/H2N3c
last change Nov 2024 re-read 2 minutes ago

A/H2N3c

Vaccine

Developed for
influenza
Investigated by
Biomedical Advanced Research and Development Authority · Seqirus

Trials 1 · a red edge is where a trial was stopped

202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05875961 Jun 2023 → Nov 2024 influenza Seqirus Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as A/H2N3c ClinicalTrials.gov intervention name — accepted as the source's own label NCT05875961
Modality Vaccine “H2N3 influenza vaccineNCT05875961
Route Intramuscular “Two intramuscular injections (3 weeks apart)” NCT05875961